Shimadzu Corporation

National Center for Geriatrics and Gerontology

The University of Tokyo

Osaka University

Naoki Kaneko

Osamu Nishimura

Masaki Mori

Takashi Nishikaze

Yuko Kobayashi

Makoto Watanabe

Yoshiki Tainaka

Katsuhiko Yanagisawa

Toshiya Matsubara

Tomonori Oshikawa

Tatsuki Okubo

Eiichi Matsuo

Taisuke Tomita

Kohei Suzuki

Akihito Korenaga

Shigeto Seno

Ritsuko Yoda

Ichiro Takemasa

Miyabishara Yokoyama

Masaya Matsuzaki

Yota Yoshizawa

Akinori Nakamura

Hideo Matsuda

The present disclosure provides a method for calibrating a difference in signal intensity ratio between machines in mass spectrometry.

Machine difference correction method for mass spectrometry apparatus

The present invention provides a method for screening a substance that controls APP669 N-terminal cleavage activity, the method comprising: causing a candidate substance to act on a cultured cell; measuring an Aβ-related peptide produced from the cultured cell; and evaluating APP669 N-terminal cleavage activity. The candidate substance is selected, for example, from the group consisting of a low molecular weight compound, a peptide, a protein, and a nucleic acid. The present invention also provides an APP669 N-terminal cleavage enzyme containing ADAMTS4.

Screening method for APP cleavage activity-controlling substances of ADAMTS4

In a sample pretreatment device, a container storage section () holds multiple containers, including a first well plate having wells in an N×M matrix form and a second well plate having N elongated wells whose length corresponds to M wells in one row of the first well plate or M elongated wells whose length corresponds to N wells in one column of the first well plate. A dispensing section () includes: a platform () on winch containers can be placed; a pipette unit () including an M-channel tip corresponding to M wells in one row of the first well plate or an N-channel tip corresponding to N wells in one column of the first well plate; and a pump unit () for suctioning/ejecting a liquid from/into a container on the platform through the pipette unit. A transfer section () transfers containers between the container storage section and the platform. A controller () controls operations of the dispensing section and the transfer section.

Sample pretreatment device

A processing method for a volatile liquid using a pipette includes a low-volatility liquid suction step of sucking a low-volatility liquid that is less volatile than the volatile liquid through the suction/ejection port, an air suction step of sucking air through the suction/ejection port after the low-volatility liquid suction step, and a volatile liquid suction step of sucking the volatile liquid through the suction/ejection port after the air suction step.

Processing method for volatile liquid and liquid processing apparatus

Provided are a biomarker for evaluating a cerebral A&#x3b2; accumulation state using amyloid precursor protein (APP)-derived A&#x3b2; and A&#x3b2;-like peptides in a living body-derived sample as an index, and a method for analysis thereof. A marker for determining a cerebral A&#x3b2; accumulation state, the marker comprising a combination of at least two ratios selected from the group consisting of: a ratio of A&#x3b2;1-39 (SEQ ID NO.: 1) level to A&#x3b2;1-42 (SEQ ID NO.: 3) level: A&#x3b2;1-39/A&#x3b2;1-42; a ratio of A&#x3b2;1-40 (SEQ ID NO.: 2) level to A&#x3b2;1-42 (SEQ ID NO.: 3) level: A&#x3b2;1-40/A&#x3b2;1-42; and a ratio of APP669-711 (SEQ ID NO.: 4) level to A&#x3b2;1-42 (SEQ ID NO.: 3) level: APP669-711/A&#x3b2;1-42, in a living body-derived sample.

Multiplex biomarker for use in evaluation of state of accumulation of amyloid B in brain, and analysis method for said evaluation

Provided are a biomarker for evaluating a cerebral A&#x3b2; accumulation state using an amyloid precursor protein (APP)-derived peptide in a living body-derived sample as an index, and a method for analysis thereof. A living body-derived sample derived from a test subject is measured, and at least one ratio selected from the group consisting of APP669-711/APP672-713 (A&#x3b2;1-42); APP672-709 (A&#x3b2;1-38)/APP672-713 (A&#x3b2;1-42); APP674-711 (A&#x3b2;3-40)/APP672-713 (A&#x3b2;1-42); APP672-710 (A&#x3b2;1-39)/APP672-713 (A&#x3b2;1-42); APP672-711 (A&#x3b2;1-40)/APP672-713 (A&#x3b2;1-42); and APP672-711 (OxA&#x3b2;1-40)/APP672-713 (A&#x3b2;1-42) is calculated, and when each of the ratios of the test subject is higher than each of standard levels which are ratios of a person having normal cognitive function NC&#x2212; who is negative for cerebral A&#x3b2; accumulation, an accumulation amount of cerebral A&#x3b2; of the test subject is determined as larger than an accumulation amount of cerebral A&#x3b2; of the person having normal cognitive function NC&#x2212;.

Surrogate biomarker for evaluating intracerebral amyloid &#xdf; peptide accumulation and method for analysis thereof

Provided is a method for measuring amyloid precursor protein (APP) cleavage peptides including amyloid beta (A&#x3b2;) peptides. A method for measuring APP cleavage peptides in a blood sample includes the steps of: bringing a blood sample into contact with an antibody-immobilizing carrier in a binding solution to bind the antibody-immobilizing carrier and APP cleavage peptides contained in the blood sample, the antibody-immobilizing carrier including a carrier, and an antibody bound to the carrier and selected from the group consisting of an immunoglobulin having an antigen binding site capable of recognizing APP cleavage peptides and an immunoglobulin fragment containing an antigen binding site capable of recognizing APP cleavage peptides; washing a bound body of the antibody-immobilizing carrier and the APP cleavage peptides using a washing solution; dissociating the APP cleavage peptides from the antibody-immobilizing carrier using an acidic aqueous solution containing an organic solvent; and detecting the dissociated APP cleavage peptides.

Measurement method for amyloid precursor protein cleavage peptides

Provided is a method for measuring a target polypeptide in a biological sample abundantly containing impurities by mass spectrometry. A method for measuring a target polypeptide in a biological sample includes: a first reaction step of bringing a liquid containing a biological sample into contact with a first antibody-immobilizing carrier to bind the target polypeptide in the biological sample with the first carrier; a first washing step of washing the first carrier; a first eluting step of eluting the target polypeptide from the first carrier by using an acidic solution to obtain a first eluate; a neutralizing step of obtaining a first purified solution by adding a neutral buffer to the first eluate; a second reaction step of bringing the first purified solution into contact with a second antibody-immobilizing carrier, to bind the target polypeptide in the first purified solution with the second carrier; a second washing step of washing the second carrier; a second eluting step of eluting the target polypeptide from the second carrier by using an acidic solution to obtain a second purified solution; and a step of detecting the target polypeptide in the second purified solution by mass spectrometry.

Mass spectrometry method for polypeptides

The present invention provides a specific combination of colon cancer markers based on statistical knowledge, which is capable of detecting a larger number of colon cancer patients in an earlier stage while maintaining high specificity. A multiplex colon cancer marker panel comprising a combination of five colon cancer markers of Carcinoembryonic antigen-related cell adhesion molecule 5, Carbohydrate antigen 19-9, Galectin-4, APEX nuclease and Actin-related protein 2. A method for analyzing colon cancer markers using multiplex colon cancer marker panel.

Multiplex colon cancer marker panel

Growing community of inventors

Kyoto, Japan

Naoki Kaneko